StockData
Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc. (ARWR) stock

ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$43.11+0.12 (+0.28%)

Close on Nov 18, 2026Market cap $6.09BP/E –Yield –

Arrowhead Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Arrowhead Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$226.44M. For fiscal 2025 it was $98.35M. The highest annual figure on record is $98.35M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Sep 30, 2025$98.35M–
FY2024Sep 30, 2024-$601.08M–
FY2023Sep 30, 2023-$205.00M–
FY2022Sep 30, 2022-$178.51M–
FY2021Sep 30, 2021-$149.04M–
FY2020Sep 30, 2020-$93.16M-252.2%
FY2019Sep 30, 2019$61.19M–
FY2018Sep 30, 2018-$55.94M–
FY2017Sep 30, 2017-$37.00M–
FY2016Sep 30, 2016-$81.74M–
FY2015Sep 30, 2015-$95.97M–
FY2014Sep 30, 2014-$53.28M–
FY2013Sep 30, 2013-$24.59M–
FY2012Sep 30, 2012-$21.09M–
FY2011Sep 30, 2011-$9.83M–
FY2010Sep 30, 2010-$5.83M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026-$170.09M–
Q2 FY2026CQ1 2026Mar 31, 2026-$141.26M-137.1%
Q1 FY2026CQ4 2025Dec 31, 2025$40.81M–
Q4 FY2025CQ3 2025Sep 30, 2025$44.11M–
Q3 FY2025CQ2 2025Jun 30, 2025-$165.55M–
Q2 FY2025CQ1 2025Mar 31, 2025$381.20M–
Q1 FY2025CQ4 2024Dec 31, 2024-$161.41M–
Q4 FY2024CQ3 2024Sep 30, 2024-$162.20M–
Q3 FY2024CQ2 2024Jun 30, 2024-$176.14M–
Q2 FY2024CQ1 2024Mar 31, 2024-$126.19M-362.0%
Q1 FY2024CQ4 2023Dec 31, 2023-$136.55M–
Q4 FY2023CQ3 2023Sep 30, 2023-$108.33M–
Q3 FY2023CQ2 2023Jun 30, 2023-$102.70M–
Q2 FY2023CQ1 2023Mar 31, 2023$48.17M+15.9%
Q1 FY2023CQ4 2022Dec 31, 2022-$42.13M–
Q4 FY2022CQ3 2022Sep 30, 2022-$83.83M–
Q3 FY2022CQ2 2022Jun 30, 2022-$72.91M–
Q2 FY2022CQ1 2022Mar 31, 2022$41.55M–
Q1 FY2022CQ4 2021Dec 31, 2021-$63.32M–
Q4 FY2021CQ3 2021Sep 30, 2021-$64.88M–
Q3 FY2021CQ2 2021Jun 30, 2021-$31.87M–
Q2 FY2021CQ1 2021Mar 31, 2021-$28.23M–
Q1 FY2021CQ4 2020Dec 31, 2020-$24.05M–
Q4 FY2020CQ3 2020Sep 30, 2020-$50.12M-620.0%
Q3 FY2020CQ2 2020Jun 30, 2020-$15.95M-185.8%
Q2 FY2020CQ1 2020Mar 31, 2020-$22.24M-201.0%
Q1 FY2020CQ4 2019Dec 31, 2019-$4.85M-144.3%
Q4 FY2019CQ3 2019Sep 30, 2019$9.64M–
Q3 FY2019CQ2 2019Jun 30, 2019$18.60M–
Q2 FY2019CQ1 2019Mar 31, 2019$22.01M–
Q1 FY2019CQ4 2018Dec 31, 2018$10.95M–
Q4 FY2018CQ3 2018Sep 30, 2018-$11.17M–
Q3 FY2018CQ2 2018Jun 30, 2018-$15.92M–
Q2 FY2018CQ1 2018Mar 31, 2018-$15.03M–
Q1 FY2018CQ4 2017Dec 31, 2017-$13.81M–
Q4 FY2017CQ3 2017Sep 30, 2017-$10.25M–
Q3 FY2017CQ2 2017Jun 30, 2017-$5.71M–
Q2 FY2017CQ1 2017Mar 31, 2017-$6.13M–
Q1 FY2017CQ4 2016Dec 31, 2016-$14.90M–
Q4 FY2016CQ3 2016Sep 30, 2016-$21.80M–

More Arrowhead Pharmaceuticals figures

See a number that looks wrong?